stockrow
Friday 6 November 2026
Export AWHL’s income statement to Excel — free account
Aspira Women's Health Inc.
AWHL Healthcare Diagnostics & Research
Aspira Women's Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.2 million, roughly unchanged from fiscal 2024.
- Revenue
- −14.9%
- EPS
- +28.6%
- Free cash flow
- −24.6%
- Total debt
- +25.9%
Quarter to June 2026, against a year earlier
0.16
0.03
−15.79%
Follow AWHL
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.12 | 1.76 | 2.33 | 1.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.03) | (43.61) | (10.85) | (84.10) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.29 | 1.95 | 2.33 | 1.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.30) | (4.06) | (3.06) | (2.53) | |
EV/FCF |
(4.15) | (4.04) | (3.05) | (2.52) | |
Quick Ratio |
0.37 | 0.49 | 0.85 | 1.22 | |
Current Ratio |
0.52 | 0.68 | 1.17 | 1.39 | |
Net Debt/EBITDA |
(0.82) | (0.81) | (0.01) | 1.62 | |
Debt/Assets |
43.88% | 60.75% | 32.44% | 18.28% | |
Debt/Equity |
(0.27) | (0.50) | (0.26) | (0.31) | |
Asset Turnover |
1.82 | 1.51 | 1.68 | 1.55 | |
Operating CF/Net income |
0.83 | (0.53) | 0.59 | 0.04 | |
Capex/Depreciation |
(3.75) | 0.00 | (0.21) | (7.86) | |
Interest Coverage |
(8.08) | (9.54) | (1,284.00) | (121.46) | |
Research and Development Expense of Revenue |
33.82% | 62.33% | 20.74% | 32.06% | |
Selling, General and Administrative Expense of Revenue |
111.14% | 104.12% | 101.44% | 96.44% | |
Intangible Assets out of Total Assets |
0.06 | 0.05 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
0.93% | 2.14% | 16.88% | 1.56% | |
Graham Net Nets |
(0.49) | (0.48) | (0.39) | (0.33) | |
Graham Number |
0.95 | 0.92 | 1.30 | 1.00 | |
Earnings Yield |
(59.51%) | (73.33%) | (58.65%) | (75.51%) | |
Free Cash Flow Yield |
(26.06%) | (27.49%) | (32.80%) | (34.18%) | |
Revenue per Share |
0.05 | 0.05 | 0.07 | 0.06 | |
Operating CF per Share |
(0.05) | (0.01) | (0.06) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.05) | (0.01) | (0.06) | (0.02) | |
Cash per Share |
0.01 | 0.03 | 0.05 | 0.10 | |
Shareholders Equity per Share |
(0.16) | (0.14) | (0.20) | (0.12) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.16) | (0.14) | (0.20) | (0.12) | |
Free Cash Flow |
(2.16) | (0.36) | (1.99) | (0.60) | |
Working Capital |
(2.54) | (1.81) | 0.60 | 1.63 | |
Capital Expenditures |
(0.15) | — | (0.01) | (0.39) | |
Net Current Asset Value |
(8.89) | (7.51) | (8.32) | (5.81) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.00 | 0.00 | 0.17 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.38 | 1.26 | 1.10 | 1.29 | |
Average Payables |
2.25 | 1.71 | 1.71 | 2.18 | |
Average Inventory |
0.25 | 0.28 | 0.29 | 0.29 | |
Average Assets |
4.68 | 5.90 | 5.47 | 6.03 | |
Average Common Equity |
(4.97) | (3.13) | (4.75) | (3.43) |
Columns are period end dates · fundamentals updated 25 Oct 2026